BioCentury
ARTICLE | Clinical News

Novocure planning submission for TTFields in mesothelioma

September 14, 2018 7:15 PM UTC

Novocure Ltd. (NASDAQ:NVCR) reported final data from the Phase II STELLAR trial to treat previously untreated unresectable malignant pleural mesothelioma showing that its Tumor Treating Fields (TTFields) plus standard of care (SOC) chemotherapy significantly improved median overall survival (OS), the primary endpoint, vs. historical controls who received SOC alone (18.2 vs. 12.1 months). On a secondary endpoint, TTFields plus SOC led to median progression-free survival (PFS) of 7.6 months vs. 5.7 months for SOC alone. TTFields plus SOC led to a partial response rate of 40.3% and a clinical benefit rate (CBR) of 97.2%.

The open-label, single-arm, European trial enrolled 80 patients to receive TTFields applied to the thorax in combination with pemetrexed plus cisplatin or carboplatin. Data will be presented at the World Conference on Lung Cancer in Toronto on Sept. 25...

BCIQ Company Profiles

Novocure GmbH